nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—Hedgehog Signaling Pathway—GLI1—urinary bladder cancer	0.046	0.158	CbGpPWpGaD
Fluocinonide—SMO—prostate gland—urinary bladder cancer	0.0411	0.15	CbGeAlD
Fluocinonide—SMO—seminal vesicle—urinary bladder cancer	0.0348	0.127	CbGeAlD
Fluocinonide—NR3C1—urine—urinary bladder cancer	0.0276	0.101	CbGeAlD
Fluocinonide—SMO—urethra—urinary bladder cancer	0.0275	0.1	CbGeAlD
Fluocinonide—Application site burn—Fluorouracil—urinary bladder cancer	0.024	0.0552	CcSEcCtD
Fluocinonide—SMO—female reproductive system—urinary bladder cancer	0.0224	0.0819	CbGeAlD
Fluocinonide—Telangiectasia—Fluorouracil—urinary bladder cancer	0.0213	0.0491	CcSEcCtD
Fluocinonide—SMO—vagina—urinary bladder cancer	0.0203	0.074	CbGeAlD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—TP63—urinary bladder cancer	0.0194	0.0667	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—GLI1—urinary bladder cancer	0.0191	0.0656	CbGpPWpGaD
Fluocinonide—SERPINA6—renal system—urinary bladder cancer	0.0154	0.0563	CbGeAlD
Fluocinonide—Allergic contact dermatitis—Fluorouracil—urinary bladder cancer	0.0144	0.0331	CcSEcCtD
Fluocinonide—Leukoderma—Thiotepa—urinary bladder cancer	0.0143	0.0329	CcSEcCtD
Fluocinonide—SMO—lymph node—urinary bladder cancer	0.0131	0.0479	CbGeAlD
Fluocinonide—SERPINA6—female reproductive system—urinary bladder cancer	0.0124	0.0451	CbGeAlD
Fluocinonide—Application site pain—Fluorouracil—urinary bladder cancer	0.0114	0.0263	CcSEcCtD
Fluocinonide—Telangiectasia—Methotrexate—urinary bladder cancer	0.0111	0.0255	CcSEcCtD
Fluocinonide—SMO—Hedgehog 'off' state—GLI1—urinary bladder cancer	0.0108	0.037	CbGpPWpGaD
Fluocinonide—Application site reaction—Fluorouracil—urinary bladder cancer	0.0107	0.0247	CcSEcCtD
Fluocinonide—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.0105	0.036	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Valrubicin—urinary bladder cancer	0.00993	0.0229	CcSEcCtD
Fluocinonide—NR3C1—prostate gland—urinary bladder cancer	0.00992	0.0362	CbGeAlD
Fluocinonide—SMO—Signaling by Hedgehog—GLI1—urinary bladder cancer	0.00963	0.0331	CbGpPWpGaD
Fluocinonide—NR3C1—seminal vesicle—urinary bladder cancer	0.00839	0.0306	CbGeAlD
Fluocinonide—Secondary infection—Epirubicin—urinary bladder cancer	0.00833	0.0192	CcSEcCtD
Fluocinonide—Eruption—Gemcitabine—urinary bladder cancer	0.00831	0.0191	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—urinary bladder cancer	0.00771	0.0177	CcSEcCtD
Fluocinonide—SMO—Hedgehog 'off' state—RBX1—urinary bladder cancer	0.00739	0.0254	CbGpPWpGaD
Fluocinonide—NR3C1—epithelium—urinary bladder cancer	0.00729	0.0266	CbGeAlD
Fluocinonide—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00702	0.0256	CbGeAlD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00694	0.0238	CbGpPWpGaD
Fluocinonide—NR3C1—renal system—urinary bladder cancer	0.00676	0.0247	CbGeAlD
Fluocinonide—NR3C1—urethra—urinary bladder cancer	0.00664	0.0242	CbGeAlD
Fluocinonide—SMO—Signaling by Hedgehog—RBX1—urinary bladder cancer	0.0066	0.0227	CbGpPWpGaD
Fluocinonide—Leukoderma—Methotrexate—urinary bladder cancer	0.00615	0.0142	CcSEcCtD
Fluocinonide—Dermatitis contact—Thiotepa—urinary bladder cancer	0.00601	0.0138	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.006	0.0206	CbGpPWpGaD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—CREBBP—urinary bladder cancer	0.00587	0.0202	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Thiotepa—urinary bladder cancer	0.0058	0.0134	CcSEcCtD
Fluocinonide—Infection—Carboplatin—urinary bladder cancer	0.00576	0.0133	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—urinary bladder cancer	0.00576	0.0133	CcSEcCtD
Fluocinonide—NR3C1—female reproductive system—urinary bladder cancer	0.00541	0.0197	CbGeAlD
Fluocinonide—Leukoderma—Doxorubicin—urinary bladder cancer	0.00533	0.0123	CcSEcCtD
Fluocinonide—Erythema—Mitomycin—urinary bladder cancer	0.00528	0.0122	CcSEcCtD
Fluocinonide—Dermatitis contact—Fluorouracil—urinary bladder cancer	0.00497	0.0114	CcSEcCtD
Fluocinonide—Pain—Carboplatin—urinary bladder cancer	0.00496	0.0114	CcSEcCtD
Fluocinonide—NR3C1—vagina—urinary bladder cancer	0.0049	0.0179	CbGeAlD
Fluocinonide—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00488	0.0112	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.00475	0.0163	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00457	0.0157	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00455	0.0105	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.00454	0.0156	CbGpPWpGaD
Fluocinonide—Pruritus—Valrubicin—urinary bladder cancer	0.00443	0.0102	CcSEcCtD
Fluocinonide—Eruption—Methotrexate—urinary bladder cancer	0.00425	0.00979	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—urinary bladder cancer	0.00417	0.00959	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—urinary bladder cancer	0.00416	0.00958	CcSEcCtD
Fluocinonide—Dizziness—Valrubicin—urinary bladder cancer	0.00414	0.00953	CcSEcCtD
Fluocinonide—Swelling—Fluorouracil—urinary bladder cancer	0.00414	0.00952	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.004	0.0137	CbGpPWpGaD
Fluocinonide—Eruption—Epirubicin—urinary bladder cancer	0.00398	0.00916	CcSEcCtD
Fluocinonide—Rash—Valrubicin—urinary bladder cancer	0.00395	0.00908	CcSEcCtD
Fluocinonide—Dermatitis—Valrubicin—urinary bladder cancer	0.00394	0.00908	CcSEcCtD
Fluocinonide—Headache—Valrubicin—urinary bladder cancer	0.00392	0.00903	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—urinary bladder cancer	0.00389	0.00896	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—MYC—urinary bladder cancer	0.00388	0.0133	CbGpPWpGaD
Fluocinonide—Nasal congestion—Cisplatin—urinary bladder cancer	0.0038	0.00874	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—urinary bladder cancer	0.00379	0.013	CbGpPWpGaD
Fluocinonide—Pain—Mitomycin—urinary bladder cancer	0.00369	0.00849	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—urinary bladder cancer	0.00368	0.00847	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00366	0.0126	CbGpPWpGaD
Fluocinonide—Folliculitis—Doxorubicin—urinary bladder cancer	0.0036	0.00829	CcSEcCtD
Fluocinonide—Swelling—Etoposide—urinary bladder cancer	0.00359	0.00827	CcSEcCtD
Fluocinonide—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.00344	0.00792	CcSEcCtD
Fluocinonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.0034	0.0117	CbGpPWpGaD
Fluocinonide—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00336	0.0116	CbGpPWpGaD
Fluocinonide—Dry skin—Fluorouracil—urinary bladder cancer	0.00335	0.0077	CcSEcCtD
Fluocinonide—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00326	0.00751	CcSEcCtD
Fluocinonide—NR3C1—lymph node—urinary bladder cancer	0.00317	0.0115	CbGeAlD
Fluocinonide—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00309	0.00712	CcSEcCtD
Fluocinonide—Glycosuria—Epirubicin—urinary bladder cancer	0.00302	0.00695	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.00291	0.00999	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00289	0.00666	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.00288	0.0099	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.00286	0.00981	CbGpPWpGaD
Fluocinonide—Dizziness—Mitomycin—urinary bladder cancer	0.00285	0.00656	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—urinary bladder cancer	0.0028	0.00643	CcSEcCtD
Fluocinonide—Immune system disorder—Thiotepa—urinary bladder cancer	0.00276	0.00635	CcSEcCtD
Fluocinonide—Rash—Mitomycin—urinary bladder cancer	0.00272	0.00626	CcSEcCtD
Fluocinonide—Dermatitis—Mitomycin—urinary bladder cancer	0.00272	0.00625	CcSEcCtD
Fluocinonide—Headache—Mitomycin—urinary bladder cancer	0.0027	0.00622	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00266	0.00913	CbGpPWpGaD
Fluocinonide—Erythema—Thiotepa—urinary bladder cancer	0.00266	0.00612	CcSEcCtD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00265	0.00911	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.00253	0.0087	CbGpPWpGaD
Fluocinonide—Skin exfoliation—Methotrexate—urinary bladder cancer	0.0025	0.00575	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—urinary bladder cancer	0.00242	0.00557	CcSEcCtD
Fluocinonide—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00234	0.00538	CcSEcCtD
Fluocinonide—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00232	0.00534	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00225	0.00517	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00224	0.00515	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.00224	0.00768	CbGpPWpGaD
Fluocinonide—Erythema—Gemcitabine—urinary bladder cancer	0.00224	0.00514	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.00223	0.00765	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.00222	0.00762	CbGpPWpGaD
Fluocinonide—Erythema—Fluorouracil—urinary bladder cancer	0.0022	0.00506	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.00216	0.00498	CcSEcCtD
Fluocinonide—Immune system disorder—Cisplatin—urinary bladder cancer	0.00216	0.00498	CcSEcCtD
Fluocinonide—Infection—Thiotepa—urinary bladder cancer	0.00215	0.00496	CcSEcCtD
Fluocinonide—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00213	0.0049	CcSEcCtD
Fluocinonide—Skin disorder—Thiotepa—urinary bladder cancer	0.00211	0.00485	CcSEcCtD
Fluocinonide—Erythema—Cisplatin—urinary bladder cancer	0.00208	0.0048	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.00204	0.00701	CbGpPWpGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.00204	0.00701	CbGpPWpGaD
Fluocinonide—Immune system disorder—Etoposide—urinary bladder cancer	0.00198	0.00456	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.00195	0.00668	CbGpPWpGaD
Fluocinonide—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.00193	0.00664	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.00192	0.0066	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00189	0.00435	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.00186	0.00639	CbGpPWpGaD
Fluocinonide—Pain—Thiotepa—urinary bladder cancer	0.00185	0.00427	CcSEcCtD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.00183	0.00627	CbGpPWpGaD
Fluocinonide—Infection—Gemcitabine—urinary bladder cancer	0.00181	0.00417	CcSEcCtD
Fluocinonide—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00179	0.00412	CcSEcCtD
Fluocinonide—Infection—Fluorouracil—urinary bladder cancer	0.00178	0.0041	CcSEcCtD
Fluocinonide—Skin disorder—Gemcitabine—urinary bladder cancer	0.00177	0.00408	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00176	0.00405	CcSEcCtD
Fluocinonide—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00176	0.00405	CcSEcCtD
Fluocinonide—Infection—Cisplatin—urinary bladder cancer	0.00169	0.00389	CcSEcCtD
Fluocinonide—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00167	0.00384	CcSEcCtD
Fluocinonide—Skin disorder—Cisplatin—urinary bladder cancer	0.00165	0.0038	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.00163	0.00559	CbGpPWpGaD
Fluocinonide—Dry skin—Epirubicin—urinary bladder cancer	0.00163	0.00375	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00161	0.00371	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00161	0.00554	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.0016	0.00368	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.00159	0.00547	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00159	0.00366	CcSEcCtD
Fluocinonide—Pain—Gemcitabine—urinary bladder cancer	0.00156	0.00359	CcSEcCtD
Fluocinonide—Infection—Etoposide—urinary bladder cancer	0.00155	0.00356	CcSEcCtD
Fluocinonide—Pruritus—Thiotepa—urinary bladder cancer	0.00153	0.00353	CcSEcCtD
Fluocinonide—Pain—Fluorouracil—urinary bladder cancer	0.00153	0.00353	CcSEcCtD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.00153	0.00526	CbGpPWpGaD
Fluocinonide—Skin disorder—Etoposide—urinary bladder cancer	0.00151	0.00348	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—urinary bladder cancer	0.00151	0.00347	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00147	0.00505	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00147	0.00338	CcSEcCtD
Fluocinonide—Pain—Cisplatin—urinary bladder cancer	0.00145	0.00335	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.00144	0.00494	CbGpPWpGaD
Fluocinonide—Dizziness—Thiotepa—urinary bladder cancer	0.00143	0.0033	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00142	0.00487	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.00139	0.00478	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.00139	0.00477	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00139	0.00319	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.00137	0.00471	CbGpPWpGaD
Fluocinonide—Rash—Thiotepa—urinary bladder cancer	0.00137	0.00315	CcSEcCtD
Fluocinonide—Dermatitis—Thiotepa—urinary bladder cancer	0.00137	0.00314	CcSEcCtD
Fluocinonide—Headache—Thiotepa—urinary bladder cancer	0.00136	0.00313	CcSEcCtD
Fluocinonide—Pain—Etoposide—urinary bladder cancer	0.00133	0.00307	CcSEcCtD
Fluocinonide—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.00133	0.00457	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.00133	0.00457	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.00132	0.00455	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00132	0.00304	CcSEcCtD
Fluocinonide—Pruritus—Gemcitabine—urinary bladder cancer	0.00129	0.00297	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.00129	0.00442	CbGpPWpGaD
Fluocinonide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00128	0.00295	CcSEcCtD
Fluocinonide—Pruritus—Fluorouracil—urinary bladder cancer	0.00127	0.00292	CcSEcCtD
Fluocinonide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00125	0.00288	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.00125	0.0043	CbGpPWpGaD
Fluocinonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.00124	0.00427	CbGpPWpGaD
Fluocinonide—Immune system disorder—Methotrexate—urinary bladder cancer	0.00119	0.00273	CcSEcCtD
Fluocinonide—Dizziness—Fluorouracil—urinary bladder cancer	0.00119	0.00273	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—HDAC4—urinary bladder cancer	0.00117	0.00403	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.00115	0.00396	CbGpPWpGaD
Fluocinonide—Rash—Gemcitabine—urinary bladder cancer	0.00115	0.00265	CcSEcCtD
Fluocinonide—Dermatitis—Gemcitabine—urinary bladder cancer	0.00115	0.00265	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—urinary bladder cancer	0.00115	0.00264	CcSEcCtD
Fluocinonide—Erythema—Methotrexate—urinary bladder cancer	0.00114	0.00263	CcSEcCtD
Fluocinonide—Headache—Gemcitabine—urinary bladder cancer	0.00114	0.00263	CcSEcCtD
Fluocinonide—Rash—Fluorouracil—urinary bladder cancer	0.00113	0.0026	CcSEcCtD
Fluocinonide—Dermatitis—Fluorouracil—urinary bladder cancer	0.00113	0.0026	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.00113	0.00388	CbGpPWpGaD
Fluocinonide—Headache—Fluorouracil—urinary bladder cancer	0.00112	0.00259	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.00112	0.00384	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.00111	0.00382	CbGpPWpGaD
Fluocinonide—Immune system disorder—Epirubicin—urinary bladder cancer	0.00111	0.00256	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—urinary bladder cancer	0.0011	0.00254	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00109	0.00373	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.00108	0.00369	CbGpPWpGaD
Fluocinonide—Rash—Cisplatin—urinary bladder cancer	0.00107	0.00247	CcSEcCtD
Fluocinonide—Dermatitis—Cisplatin—urinary bladder cancer	0.00107	0.00247	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—urinary bladder cancer	0.00107	0.00246	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.00107	0.00366	CbGpPWpGaD
Fluocinonide—Dizziness—Etoposide—urinary bladder cancer	0.00103	0.00237	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00103	0.00236	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—urinary bladder cancer	0.00099	0.00228	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—GLI1—urinary bladder cancer	0.000984	0.00338	CbGpPWpGaD
Fluocinonide—Rash—Etoposide—urinary bladder cancer	0.000982	0.00226	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—urinary bladder cancer	0.000981	0.00226	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000976	0.00335	CbGpPWpGaD
Fluocinonide—Headache—Etoposide—urinary bladder cancer	0.000976	0.00225	CcSEcCtD
Fluocinonide—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000971	0.00333	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000967	0.00222	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000967	0.00332	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000961	0.0033	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000948	0.00326	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000933	0.0032	CbGpPWpGaD
Fluocinonide—Infection—Methotrexate—urinary bladder cancer	0.000927	0.00213	CcSEcCtD
Fluocinonide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000915	0.00211	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000908	0.00312	CbGpPWpGaD
Fluocinonide—Skin disorder—Methotrexate—urinary bladder cancer	0.000907	0.00209	CcSEcCtD
Fluocinonide—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000906	0.00311	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000905	0.00208	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000871	0.00299	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000871	0.00299	CbGpPWpGaD
Fluocinonide—Infection—Epirubicin—urinary bladder cancer	0.000868	0.002	CcSEcCtD
Fluocinonide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000857	0.00197	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—urinary bladder cancer	0.000848	0.00195	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000837	0.00193	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000833	0.00286	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000812	0.00279	CbGpPWpGaD
Fluocinonide—Infection—Doxorubicin—urinary bladder cancer	0.000803	0.00185	CcSEcCtD
Fluocinonide—Pain—Methotrexate—urinary bladder cancer	0.000798	0.00184	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000793	0.00182	CcSEcCtD
Fluocinonide—SMO—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000792	0.00272	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000788	0.00271	CbGpPWpGaD
Fluocinonide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000785	0.00181	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000784	0.00269	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000768	0.00264	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000747	0.00257	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—urinary bladder cancer	0.000747	0.00172	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.000734	0.00252	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000699	0.0024	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000696	0.00239	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000692	0.00238	CbGpPWpGaD
Fluocinonide—Pain—Doxorubicin—urinary bladder cancer	0.000691	0.00159	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000688	0.00158	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—RBX1—urinary bladder cancer	0.000674	0.00231	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.000666	0.00229	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000665	0.00228	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.00066	0.00227	CbGpPWpGaD
Fluocinonide—Pruritus—Methotrexate—urinary bladder cancer	0.00066	0.00152	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000658	0.00226	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000651	0.00224	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000643	0.00148	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—TSC1—urinary bladder cancer	0.000634	0.00218	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—urinary bladder cancer	0.000618	0.00142	CcSEcCtD
Fluocinonide—Dizziness—Methotrexate—urinary bladder cancer	0.000617	0.00142	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—JAG1—urinary bladder cancer	0.000603	0.00207	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000595	0.00137	CcSEcCtD
Fluocinonide—Rash—Methotrexate—urinary bladder cancer	0.000588	0.00135	CcSEcCtD
Fluocinonide—Dermatitis—Methotrexate—urinary bladder cancer	0.000588	0.00135	CcSEcCtD
Fluocinonide—Headache—Methotrexate—urinary bladder cancer	0.000585	0.00135	CcSEcCtD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000579	0.00199	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000578	0.00198	CbGpPWpGaD
Fluocinonide—Dizziness—Epirubicin—urinary bladder cancer	0.000578	0.00133	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—urinary bladder cancer	0.000572	0.00132	CcSEcCtD
Fluocinonide—Rash—Epirubicin—urinary bladder cancer	0.000551	0.00127	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—urinary bladder cancer	0.00055	0.00127	CcSEcCtD
Fluocinonide—Headache—Epirubicin—urinary bladder cancer	0.000547	0.00126	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000535	0.00184	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—urinary bladder cancer	0.000534	0.00123	CcSEcCtD
Fluocinonide—Rash—Doxorubicin—urinary bladder cancer	0.00051	0.00117	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000509	0.00117	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—urinary bladder cancer	0.000506	0.00117	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—S100B—urinary bladder cancer	0.000489	0.00168	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.000479	0.00164	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.000471	0.00162	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—RHOA—urinary bladder cancer	0.000463	0.00159	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000459	0.00158	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000459	0.00158	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—NCOR1—urinary bladder cancer	0.000439	0.00151	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000407	0.0014	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000394	0.00135	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL2—urinary bladder cancer	0.000389	0.00133	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TERT—urinary bladder cancer	0.000387	0.00133	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.00037	0.00127	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FGFR3—urinary bladder cancer	0.000355	0.00122	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000355	0.00122	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ESR1—urinary bladder cancer	0.000345	0.00118	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000319	0.0011	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CREBBP—urinary bladder cancer	0.000302	0.00104	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1—urinary bladder cancer	0.000299	0.00103	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—EGFR—urinary bladder cancer	0.000297	0.00102	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—KRAS—urinary bladder cancer	0.000281	0.000964	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000279	0.000956	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RHOA—urinary bladder cancer	0.000274	0.00094	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000254	0.000873	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000254	0.000871	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ERBB2—urinary bladder cancer	0.000253	0.00087	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000244	0.000838	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CXCL8—urinary bladder cancer	0.00024	0.000825	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—HRAS—urinary bladder cancer	0.000239	0.000819	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL2—urinary bladder cancer	0.00023	0.000788	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CCND1—urinary bladder cancer	0.000224	0.000768	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000221	0.000759	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MMP9—urinary bladder cancer	0.000217	0.000746	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000217	0.000743	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTEN—urinary bladder cancer	0.000216	0.000742	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EP300—urinary bladder cancer	0.000206	0.000707	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—SRC—urinary bladder cancer	0.0002	0.000688	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MYC—urinary bladder cancer	0.00018	0.000616	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGFR—urinary bladder cancer	0.000176	0.000603	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	0.000171	0.000586	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KRAS—urinary bladder cancer	0.000166	0.00057	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	0.000161	0.000551	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—urinary bladder cancer	0.000147	0.000506	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000145	0.000497	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—HRAS—urinary bladder cancer	0.000141	0.000484	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—ESR1—urinary bladder cancer	0.000134	0.00046	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—PPARG—urinary bladder cancer	0.000122	0.00042	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	0.000118	0.000404	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MYC—urinary bladder cancer	6.98e-05	0.00024	CbGpPWpGaD
